【摘要】：動(dòng)脈粥樣硬化是臨床常見疾病,是缺血性心腦血管病的主要病理基礎(chǔ)。迄今為止,其發(fā)病機(jī)制尚未完全清楚,因而臨床尚無有效而特異性的藥物治療。大量基礎(chǔ)和臨床研究表明,動(dòng)脈粥樣硬化是一種慢性炎癥性疾病,是血管壁對(duì)各種損傷的一種異常反應(yīng),具有經(jīng)典炎癥變性、滲出及增生的特點(diǎn)。炎癥反應(yīng)貫穿動(dòng)脈粥樣硬化發(fā)病的各個(gè)階段,可能是多種致動(dòng)脈粥樣硬化因素致病機(jī)制的共同環(huán)節(jié)或通路。炎癥機(jī)制不但與動(dòng)脈粥樣硬化的發(fā)生發(fā)展有關(guān),而且與動(dòng)脈粥樣硬化的多種并發(fā)癥的發(fā)生密切相關(guān)。動(dòng)脈粥樣硬化的炎癥類型包括生物性炎癥、免疫性炎癥和化學(xué)性炎癥。動(dòng)脈粥樣硬化發(fā)病初期主要表現(xiàn)為急性滲出性炎癥,而在進(jìn)展期主要表現(xiàn)出慢性增生性炎癥的特點(diǎn)。炎癥反應(yīng)中涉及多種炎癥細(xì)胞、炎性細(xì)胞因子、炎性介質(zhì)、黏附分子、趨化因子、生長因子等�，F(xiàn)已證明,多種抗動(dòng)脈粥樣硬化藥物具有抗炎作用,抗炎治療已成為防治動(dòng)脈粥樣硬化的一種新途徑。
[Abstract]:Atherosclerosis is a common clinical disease, is the main pathological basis of ischemic cardiovascular and cerebrovascular disease. So far, the pathogenesis of the disease has not been fully understood, so there is no effective and specific drug therapy. A large number of basic and clinical studies have shown that atherosclerosis is a chronic inflammatory disease, is an abnormal response of vascular wall to various injuries, and has the characteristics of classic inflammatory degeneration, exudation and proliferation. Inflammatory reaction runs through the various stages of atherosclerosis and may be the common link or pathway of the pathogenesis of various atherogenic factors. Inflammatory mechanism is not only related to the occurrence and development of atherosclerosis, but also closely related to the occurrence of various complications of atherosclerosis. Inflammatory types of atherosclerosis include biological inflammation, immune inflammation and chemical inflammation. Acute exudative inflammation is the main manifestation in the early stage of atherosclerosis, and chronic proliferative inflammation in the advanced stage. Inflammatory response involves many inflammatory cells, inflammatory cytokines, inflammatory mediators, adhesion molecules, chemokines, growth factors and so on. It has been proved that many anti-atherosclerotic drugs have anti-inflammatory effects and anti-inflammatory therapy has become a new way to prevent and treat atherosclerosis.
【作者單位】： 西安交通大學(xué)醫(yī)學(xué)部基礎(chǔ)醫(yī)學(xué)院藥理系;
【基金】：2007年國家自然科學(xué)基金(No.30772567) 2006年教育部博士學(xué)科點(diǎn)專項(xiàng)科研基金(No.20060698048) 2010年教育部博士學(xué)科點(diǎn)專項(xiàng)科研基金(No.20100201110053)~~
【分類號(hào)】：R543.5

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 馬亞兵;高海青;;微量元素與動(dòng)脈粥樣硬化[J];國外醫(yī)學(xué)(老年醫(yī)學(xué)分冊);2006年06期

2 王桂斌;蔣立;史艷萍;劉運(yùn)海;;HCMV感染與動(dòng)脈粥樣硬化及動(dòng)脈硬化性缺血性腦血管病相關(guān)性研究進(jìn)展[J];國際神經(jīng)病學(xué)神經(jīng)外科學(xué)雜志;2008年01期

3 鐘華榮;呂安康;沈衛(wèi)峰;;從分子機(jī)制探討肥胖致動(dòng)脈粥樣硬化[J];國際心血管病雜志;2007年05期

4 陳q，

本文編號(hào)：2121426